Jubilant Awarded Radiopharmaceutical Group Purchasing Agreement by Premier

Press Release (ePRNews.com) - YARDLEY, Pa. - Oct 25, 2019 - The Radiopharma Division of Jubilant Pharma Limited, announced today that under its Radiopharmacies business, the Company has been awarded the group purchasing agreement by Premier Inc. for its full line of radiopharmaceuticals products. The agreement becomes effective January 1, 2020, and allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for their line of radiopharmaceuticals. Additionally, Jubilant was selected as the sole-source supplier for the Premier Ascend program, which provides the Ascend members with access to enhanced value for this highly committed program.

“Jubilant is proud to be selected as a supplier by Premier to service the radiopharmaceutical needs of their members across the country,“ said Pramod Yadav, CEO, Jubilant Pharma Limited. “We have made great strides over the past few years to build a leading nuclear medicine company and are confident Premier members and their patients will benefit from the high-quality products and services to which they now have access.”

Radiopharmaceuticals are low-level radioactive drugs used by physicians. These products are carefully monitored and typically used for diagnostic purposes, in conjunction with imaging devices, to scan vital organs for diseases, but are also used as a theragnostics tool to treat certain cancers.


About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated, global pharmaceutical company engaged in the manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non‐sterile products through six USFDA approved manufacturing facilities in the U.S., Canada and India and a network of over 50 radio‐pharmacies in the U.S. The Company has a team of over 4,300 multicultural people across the globe and is committed to delivering value to its customers, spread across over 75 countries. It is well recognized as a ‘Partner of Choice’ by leading pharmaceutical companies globally.

About Jubilant Radiopharma

Jubilant Radiopharma a business division of Jubilant Pharma Limited, is an industry leader focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of Improving Lives Through Nuclear Medicine on a global scale.

Media Contact:

Robert Sgroi

Director of Marketing & New Product Opportunities


Source : Jubilant Radiopharma
Business Info :
Jubilant Radiopharma

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.